Guihua Wang
A5090646125- Thyroid Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Intensive Care Unit Cognitive Disorders
- Stroke Rehabilitation and Recovery
- Family and Patient Care in Intensive Care Units
- Pharmacological Effects of Natural Compounds
- Neurological Disorders and Treatments
- Anesthesia and Sedative Agents
- Pharmacogenetics and Drug Metabolism
- Pharmaceutical studies and practices
- Neurological Disease Mechanisms and Treatments
Changsha Central Hospital
2023
Zhongda Hospital Southeast University
2023
Aerospace Center Hospital
2021-2022
This article explores the effects of early cognitive training and rehabilitation for patients with dysfunction in stroke.Stroke have dysfunction, incidence stroke is six to nine times that without stroke. selects 118 our hospital from August 2017 2019, 42 disorders randomly divided into two groups. Both groups received conventional training, observation group performed motion therapy virtual reality equipment based on training. Analysis time parameters related before after treatment,...
The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.This multicenter, double-blind, placebo-controlled, III enrolled 191 RAIR-DTC randomized a ratio 2:1 (300 mg twice daily,...
Abstract Background COPD combined with respiratory failure is very common in intensive care unit (ICU). We aimed to evaluate the current status and influencing factors of delirium elderly patients undergoing mechanical ventilation. Methods Patients mechanically ventilated who were admitted ICU our hospital selected. The characteristics included assessed. Pearson correlation analysis was performed delirium. Logistic regression conducted identify risk Results A total 237 included, incidence...
Background: HSK21542, a novel selective peripherally-restricted κ-opioid receptor agonist has been proven to be safe and effective analgesic antipruritic drug in both vitro vivo studies. We aimed evaluate its safety, pharmacokinetics efficacy hemodialysis patients over 1-week treatment period, establish the optimal dosage for further 12-week stage 2 trial. Methods: In this multiple ascending dose study, were randomly assigned receive HSK21542 (0.05-0.80 μg/kg), or placebo three times within...
<div>Abstract<p>Purpose: The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumour activity safety RAIR-DTC patients. Patients Methods: This multicenter, double-blind, placebo-controlled, III...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>AbstractPurpose:<p>The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.</p>Patients Methods:<p>This multicenter, double-blind,...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>Abstract<p>Purpose: The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumour activity safety RAIR-DTC patients. Patients Methods: This multicenter, double-blind, placebo-controlled, III...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>AbstractPurpose:<p>The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.</p>Patients Methods:<p>This multicenter, double-blind,...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>